Clinical trial
Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy
NCT01633983 is registered in ClinicalTrials.gov with Edward Averbukh as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy
- Lead sponsor
- Edward Averbukh
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2012
- Completion date
- July 31, 2015
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.